Prev Next
Cancer Precision Medicine Panel
Our Cancer Precision Medicine Panel has been designed to detect a broad range of clinically actionable genomic variants occurring in cancer genes relevant to solid tumour diagnosis, prognosis and treatment.
The panel is designed to accept DNA isolated from a wide range of cancer sample sources and is designed to detect Single Nucleotide Variants (SNVs), insertions and deletions (indels), Copy Number Variants (CNVs), genomic signatures including Microsatellite Instability (MSI) and Loss of Heterozygosity (LOH) in key tumour suppressor genes as well as large-scale structural variants.
Our Design
Our design allows for confident exclusion of key clinically important variants using unique molecular identifiers (UMIs) that permit molecular counting and exclusion of sequence and fixation artefacts.
Variant interpretation and reporting is provided in conjunction with a leading tertiary analysis provider and includes full details of clinically actionable variants detected, variant allele frequencies, licensed therapies appropriate to tumour histology (where provided), relevant National Comprehensive Cancer Network® (NCCN®) guidance and potential eligibility for clinical trials (dependent on clinical eligibility e.g. performance status, previous treatment regimens etc).
Indications Detected
Lung Cancer (NSCLC)
Lung Cancer (NSCLC)
Colorectal Cancer including Lynch syndrome
Colorectal Cancer including Lynch syndrome
Central Nervous System (CNS) tumours
Central Nervous System (CNS) tumours
Melanoma
Melanoma
Breast Cancer
Breast Cancer
Ovarian Cancer
Ovarian Cancer
Sample Type

FFPE tissue sections (histology & cytology)

Recommended neoplastic cell content for tissue samples >10%
Reporting and Target Turnaround Time

Full clinical reporting in conjunction with a leading tertiary analysis provider
14 calendar days or less from receipt of specimen and all required clinical information
Features

Next Generation Sequencing detection of SNVs, CNVs & LOH
Industry standard Illumina SBS sequencing chemistry
Up to 88 genes
1Mb SNP backbone across 22 chromosomes (2467 SNVs)
Microsatellite Instability (MSI) characterisation
Covers core genes in the NHSE Cancer Test Directory